Asset management company of the Intesa Sanpaolo group that invests in biotechs.
Profile being verified
What they look for
Co-led the Series B extension of NUCLIDIUM; new investor in Nouscom's round. Mario Costantini, CEO and managing director, is quoted.
Recent investments
Recorded Swiss rounds: NUCLIDIUM (Series B, CHF 26 M, May 2026, co-lead), Nouscom (Series C, USD 135 M, October 2026).